Drug Profile
Hepatitis A vaccine inactivated - Merck
Alternative Names: VaqtaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Chongqing Zhifei Biological Products; CSL; Merck & Co; Merck Canada
- Class Hepatitis A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis A
Most Recent Events
- 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
- 23 Nov 2006 SBL Vaccin AB has been acquired by Crucell
- 18 Aug 2005 Registered for hepatitis A in children aged 12 months and older